Login Support

Conference on Retroviruses and Opportunistic Infections (CROI) 2022

CROI facilitates the presentation of important research discoveries in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. CROI 2022 is a fully virtual conference, starting February 12 - 16 with additional symposia on February 22, 23, and 24. 

CROI 2022 Program Guide
CROI 2022 Conference Website

Listed below are CROI 2022 oral abstract sessions (OA) and poster sessions (PS) affiliated with the HIV/AIDS Clinical Trials Networks. All sessions are listed in North American Mountain Time (MT).

Monday, February 14, 2022

Expand All
OA2: Maternal and Child Health: New Insights into Hepatitis, SARS-CoV-2
Time (MT) Abstract Title Presenting Author Protocol
10:14 AM Growth Of Infants with Perinatal Exposure to Maternal DTG vs EFV and TDF vs TAF  Lynda Stranix-Chibanda IMPAACT 2010
10:45 AM Two Year Virologic Outcomes of Very Early ART for Infants in the IMPAACT P1115 Study  Deborah Persaud IMPAACT P1115
OA3: Malignancies and Comorbidities: An Increasing Burden
Time (MT) Abstract Title Presenting Author Protocol
9:50 AM Geographical Differences in Functional Impairment of People with HIV Kristine Erlandson ACTG 5332/ REPRIEVE
OA4: Evolving Epidemiology of HIV and SARS-CoV-2
Time (MT) Abstract Title Presenting Author Protocol
10:14 AM SARS-CoV-2 Prevalence in Children and Adults in 15 US Communities: The COMPASS Study Jessica E. Justman CoVPN 5002
11:09 AM COVID-19 Vaccination Rates in a Global HIV Cohort Evelynne S. Fulda ACTG 5332/ REPRIEVE
Expand All
PS-A01: Infection and Envelope
Abstract Title Presenting Author Protocol
N-Glycosylation Site Signatures of HIV Envelope in Post-Treatment Controllers Elmira Esmaeilzadeh NWCS 380
PS-E04: Controllers and Post-Treatment Controllers
Abstract Title Presenting Author Protocol
Post-Treatment Controllers Limit Completed and Spliced HIV Transcripts After ATI Adam Wedrychowski NWCS 380
Post-Treatment Controllers Maintain a Limited Intact Reservoir After ART Interruption Yijia Li ACTG 5068
PS-F04: Blood and CSF Biomarkers of Brain Integrity and Function
Abstract Title Presenting Author Protocol
H/L-Ferritins and Tim-1 Associate with Neurocognitive Function in People with HIV Asha R. Kallianpur ACTG 5322/ HAILO
Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH Robert Kalayjian NWCS 447
PS-I02: Impact of HIV Mutations on Fitness, Drug Resistance, and Treatment Response Session
Abstract Title Presenting Author Protocol
HIV Drug Resistance in Women Randomized to DTG vs EFV or TDF vs TAF in Pregnancy Ceejay L. Boyce
 IMPAACT 2010
PS-J01: Fatty Liver: NAFL, MAFL, and NASH
Abstract Title Presenting Author Protocol
NAFLD is Common Among REPRIEVE Participants and Associated with Cardiovascular Risk Carl J. Fichtenbaum ACTG 5332/ REPRIEVE
PS-L01: Risk Factor and Inflammatory Mediators of Cardiovascular Disease
Abstract Title Presenting Author Protocol
Subclinical Atherosclerosis and Immune Activation Among US Females vs. Males with HIV Markella V. Zanni ACTG 5332/ REPRIEVE
PS-M04: Frailty and Sleep Disturbances
Abstract Title Presenting Author Protocol
L-Ferritin and Tim-1 are Associated with Frailty Measures in People with HIV Asha R. Kallianpur ACTG 5322/ HAILO
PS-N01: Post-acute Sequelae of SARS-CoV-2 Infection
Abstract Title Presenting Author Protocol
Post-Acute Sequelae of SARS-CoV-2 in NonHospitalized ACTIV-2 Trial Participants Teresa H. Evering ACTG 5401/ ACTIV-2
PS-O05: CMV and Fungal Opportunistic Infections
Abstract Title Presenting Author Protocol
ACTG A5351S: Effect of Immune-Modulatory Interventions on CMV Replication During ART Elizabeth Hastie ACTG 5351s
PS-P03: Evolving Insights: MTCT Risk to Maternal Health Session
Abstract Title Presenting Author Protocol
Pregnancy Hemoglobin A1c and glucose with DTG vs EFV, TDF vs TAF: IMPAACT 2010 Lameck Chinula IMPAACT 2010
Weight Gain with Raltegravir vs. Efavirenz During Pregnancy Conrado M. Coutinho NICHD P1081
PS-P04: New Perspectives on the Health of Children Exposed to HIV In Utero Session
Abstract Title Presenting Author Protocol
Association of Maternal TDF-containing ART with Bone Mineral Content in Breastfed Infants Tichaona Vhembo PROMISE P1084s
PS-V01: PrEP: Services, Cost-Effectiveness, Bone Loss, and ARV Resistance
Abstract Title Presenting Author Protocol
Estimating Benefits From Using On-Demand Oral PrEP by MSM in US: A Modeling Study Sarah Stansfield HPTN Modelling Centre

Tuesday, February 15, 2022

Expand All
OA5: HIV Reservoirs and Cure Strategies Session
Time (MT) Abstract Title Presenting Author Protocol
10:14 AM HIV-1 Remission with CCR5Δ32Δ32 Haplo-Cord Transplant in a US Woman: IMPAACT P1107 Yvonne Bryson IMPAACT P1107
OA6: Tuberculosis, Opportunistic Infections, and Hepatitis
Time (MT) Abstract Title Presenting Author Protocol
11:01 AM PK of Dose-Adjusted Emergency Contraception with Rifampicin Therapy in ACTG A5375 Rosie Mngqibisa ACTG 5375
11:09 AM DTG PK in People with HIV Receiving Daily 1Hp for Latent Tb Treatment Anthony T. Podany ACTG 5372
OA7: HIV Prevention: From the Bend to Population
Time (MT) Abstract Title Presenting Author Protocol
9:58 AM Phase I Study of Combination Anti-HIV Neutralizing Antibodies in HIV-Negative Adults Magdalena E. Sobieszcyk HVTN 130/ HPTN 089
11:01 AM Counterfactual Estimation of CAB-LA Efficacy Against Placebo Using External Trial Data Deborah Donnell HPTN 084
11:09 AM Different HIV Protection for Traditional and Medical Circumcision in HPTN 071 (POPART) Kidist B. Zewdie HPTN 071
OA8: Global Persperctives on HIV Testing, Treatment, and Prevention
Time (MT) Abstract Title Presenting Author Protocol
11:01 AM Updated Efficacy, Safety, and Case Studies in HPTN 083: CAB-LA vs. TDF/FTC for PrEP Raphael J. Landovitz HPTN 083
11:09 AM CAB-LA PrEP: Early Detection of HIV Infection may Reduce INSTI Resistance Risk Susan Eshleman HPTN 083
OA9: SARS-CoV-2 Antivirals and Outcomes
Time (MT) Abstract Title Presenting Author Protocol
9:50 AM Symptom Duration in COVID-19 Convalescent Patients: Regional & Clinical Associations Jorge A. Gallardo-Cartagena HVTN 405/ HPTN 1901
11:17 AM Camostat is not Effective for Mild-Moderate COVID-19 in a Phase II Trial of ACTIV-2 Nikolaus Jilg ACTG 5401/ ACTIV-2

Treatment of Anal High-grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
Presenting Author: Joel Palefsky
Protocol: ANCHOR study
Expand All
PS-D03: HIV Immunology: T Cells
Abstract Title Presenting Author Protocol
T Cells Expressing Multiple Inhibitory Receptors Persist on Long-Term ART Bernard J. Macatangay ACTG 5321
Inhibitory Receptor Expression Correlates with HIV Persistence and Immune Responses Bernard J. Macatangay ACTG 5321
HIV-Specific T Cell Frequencies and Function After ART During Acute or Early HIV Scott F. Sieg ACTG 5354
PS-E06: Dynamics of HIV Reservoirs and Viral Rebound
Abstract Title Presenting Author Protocol
Size and Activity of the HIV Reservoir Predict Rebound Timing After ART Interruption Jonathan Li ACTG 5345
Early Antiretroviral Therapy Reduces But Does Not Eliminate HIV DNA in Blood Trevor A. Crowell ACTG 5354
PS-H01: Clinical Trials of Therapy for SARS-CoV-2: Antivirals and Immune Modifiers
Abstract Title Presenting Author Protocol
Phase-2 Evaluation of Sab-185, a Polyclonal Antibody Treatment for COVID-19 in ACTIV-2 Babafemi O. Taiwo ACTG 5401/ ACTIV-2
PS-J02: HCV Treatment and Disease
Abstract Title Presenting Author Protocol
Adherence in The ACTG 5360 HCV Minimal Monitoring (MINMON) Trial Leonard Sowah ACTG 5360/ MINMON
PS-M03: Other Comorbidities
Abstract Title Presenting Author Protocol
Proteinuria is Common Among People with HIV with Controlled HIV Viremia Edgar T. Overton ACTG 5332/ REPRIEVE
PS-P01: COVID-19 in Mothers and Their Children Session
Abstract Title Presenting Author Protocol
IMPAACT 2032: Remdesivir PK & Safety in Pregnant and Non-pregnant Women with COVID-19  Kristina M. Brooks IMPAACT 2032
PS-P02: HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms Session
Abstract Title Presenting Author Protocol
Risk-benefit Trade-off for Pregnancy and Infant Outcomes: DTG, EFV, TAF, and TDF Sean Brummel IMPAACT 2010
Adverse Outcomes in Subsequent Pregnancies in the IMPAACT 2010 Trial Lee Fairlie IMPAACT 2010
Impact of Maternal Hepatitis B Virus Co- infection on Pregnancy and Infant Outcomes in the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study Flavia K. Matovu PROMISE 1077BF/1077FF
PS-Q02: Early Treatment and HIV Reservoirs in Children Session
Abstract Title Presenting Author Protocol
Is Routine PCP Prophylaxis Needed in Very Early-treated Infants with HIV? Bryan S. Nelson IMPAACT P1115
PS-R01: SARS-CoV-2 Epidemiology
Abstract Title Presenting Author Protocol
Asymptomatic SARS-CoV-2 Infection is Extremely Common Among People with HIV Edgar T. Overton ACTG 5332/ REPRIEVE
PS-V02: PrEP in Adolescents and Pregnant People
Abstract Title Presenting Author Protocol
A Tool to Assess HIV Prevention Readiness of Adolescent Girls and Young Women Geetha Beauchamp HPTN 082

Wednesday, February 16, 2022
Expand All
OA11: Crossing the CNS Border: HIV, SIV, and SARS-CoV-2
Time (MT) Abstract Title Presenting Author Protocol
11:09 AM ACTG A5324: A randomized trial of ART intensification for cognitive impairment in PWH Scott Letendre ACTG 5324
Expand All
PS-D05: HIV Immune Therapy
Abstract Title Presenting Author Protocol
Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusion in Persons with HIV Bernard J. Macatangay ACTG 5370
Ex Vivo Assay Predicts HIV-1 Suppression by bNAbs Infused in a Phase I Clinical Trial Sabrina Helmold Hait ACTG 5378
PS-E05: Immune Pressures on the HIV Reservoir
Abstract Title Presenting Author Protocol
HIV Envelope Diversity and Sensitivity to bNAbs Across Stages of Acute and Early HIV Laurie VanderVeen ACTG 5354
PS-F02: ART: Efficacy, Switches, and Toxicity
Abstract Title Presenting Author Protocol
Impact of Integrase Strand Transfer Inhibitors on Cognition in the HAILO Cohort Jane O'Halloran ACTG 5322/ HAILO
PS-H03: Antiretroviral Therapy in Experienced Patients: Sustain or Regain Suppression
Abstract Title Presenting Author Protocol
Efficacy of Tenofovir-Lamivudine-Dolutegravir for Initial and First-Line Switch ART Cissy Kityo ACTG 5381
PS-H04: First-line Therapy, Low-level Viremia, and Adherence
Abstract Title Presenting Author Protocol
Feasibility and Viral Response to Treating Acute/Early HIV in a Multinational Study Eric S. Daar ACTG 5354
PS-M01: Weight Gain and Adipose Tissue Biology
Abstract Title Presenting Author Protocol
Pharmacogenetics of Weight Gain After Switch to Integrase Inhibitor-Based Regimens David W. Haas DACS 349
PS-P05: HIV Infection and Prevention in Pregnancy
Abstract Title Presenting Author Protocol
Evaluation of CAB-LA Safety and PK in Pregnant Women in the Blinded Phase of HPTN 084 Sinead Delany-Moretlwe HPTN 084
PS-Q05: PK, Safety, and Acceptability of New Agents for Children and Youth Session
Abstract Title Presenting Author Protocol
Extended Safety and PK and Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants Coleen K. Cunningham IMPAACT P1112
IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14 kg  Kristina M. Brooks IMPAACT 2019
Safety and PK of Long-acting Cabotegravir and Rilpivirine in Adolescents Aditya H. Gaur IMPAACT 2017
Adolescent and Parent Experiences with Long- acting Injectables in the MOCHA Study Elizabeth D. Lowenthal IMPAACT 2017
PS-V04: Early Phase Studies of HIV Vaccines, bNAbs, and Next-Generation PrEP
Abstract Title Presenting Author Protocol
Expectations of Preventive Benefits and HIV-Related Risk Behaviors in HPTN 069/ACTG 5305 Jeremy Sugarman HPTN 069/ ACTG 5305